Compass Therapeutics, Inc. (OTC:CMPX – Get Rating) – Research analysts at B. Riley decreased their FY2023 earnings per share (EPS) estimates for shares of Compass Therapeutics in a note issued to investors on Tuesday, May 10th. B. Riley analyst J. Walsh now anticipates that the company will post earnings of ($0.48) per share for the year, down from their prior forecast of ($0.47). B. Riley currently has a “Buy” rating and a $10.00 price objective on the stock. B. Riley also issued estimates for Compass Therapeutics’ FY2025 earnings at ($0.67) EPS.
Several other research firms also recently commented on CMPX. Zacks Investment Research downgraded Compass Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, April 4th. HC Wainwright assumed coverage on Compass Therapeutics in a research note on Friday, January 21st. They set a “buy” rating and a $11.00 price objective for the company. Finally, LADENBURG THALM/SH SH assumed coverage on Compass Therapeutics in a research report on Tuesday, March 15th. They set a “buy” rating and a $7.00 target price on the stock. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $8.91.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Difesa Capital Management LP bought a new stake in Compass Therapeutics during the fourth quarter worth approximately $33,000. Millennium Management LLC bought a new stake in Compass Therapeutics during the fourth quarter worth approximately $35,000. Mirabella Financial Services LLP bought a new stake in Compass Therapeutics during the fourth quarter worth approximately $60,000. JPMorgan Chase & Co. bought a new stake in Compass Therapeutics during the fourth quarter worth approximately $75,000. Finally, New Capital Management LP acquired a new position in Compass Therapeutics in the fourth quarter worth approximately $77,000. 66.04% of the stock is currently owned by institutional investors.
In other Compass Therapeutics news, Director Orbimed Advisors Llc bought 90,712 shares of the business’s stock in a transaction on Monday, May 9th. The shares were purchased at an average price of $1.56 per share, with a total value of $141,510.72. Following the completion of the acquisition, the director now directly owns 14,601,031 shares of the company’s stock, valued at approximately $22,777,608.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas J. Schuetz purchased 27,836 shares of the business’s stock in a transaction dated Tuesday, May 10th. The shares were acquired at an average cost of $1.80 per share, for a total transaction of $50,104.80. Following the acquisition, the chief executive officer now owns 5,153,303 shares of the company’s stock, valued at approximately $9,275,945.40. The disclosure for this purchase can be found here. Insiders have bought 128,748 shares of company stock valued at $208,242 over the last 90 days.
About Compass Therapeutics (Get Rating)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, develops proprietary antibody-based therapeutics to treat multiple human diseases. The company's product candidates include CTX-009, an investigational bispecific antibody, which is in Phase II clinical trial for biliary tract cancers, as well as Phase Ib clinical trial for colorectal and ovarian cancer; CTX-471, a monoclonal antibody product candidate that is in Phase I clinical trial for patients with solid tumors, such as small cell lung cancer and melanoma; and CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 for oncology area.
- Get a free copy of the StockNews.com research report on Compass Therapeutics (CMPX)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.